- Investing.com
Promising Pipeline | Explore Merus N.V.'s innovative multispecific antibody platform, with lead candidate petosemtamab showing strong potential in HNSCC and CRC treatments |
Clinical Milestones | Delve into petosemtamab's impressive Phase 2 results, including a 63% ORR in combination therapy and promising monotherapy outcomes in HNSCC |
Market Potential | Analysts project U.S. peak sales of $3 billion for petosemtamab in HNSCC alone, with additional upside from potential colorectal cancer indications |
Financial Outlook | Despite current losses, Merus maintains a strong cash position. Analyst price targets range from $67 to $109, with profitability expected by 2027 |
Metrics to compare | MRUS | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipMRUSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −3.0x | −0.4x | |
PEG Ratio | 0.00 | 0.04 | 0.00 | |
Price/Book | 0.0x | 2.9x | 2.6x | |
Price / LTM Sales | 0.0x | 7.2x | 3.0x | |
Upside (Analyst Target) | 0.0% | 338.0% | 54.8% | |
Fair Value Upside | Unlock | 5.8% | 9.0% | Unlock |